Maze Therapeutics Q2 Net Loss $(44.7M); Raises $144.6M Equity, $40M Debt

Maze Therapeutics reported a net loss of $44.7 million for Q2 2026, an increase from $33.7 million in Q2 2025. Year-to-date 2026 net loss was $68.9 million, compared to $66.5 million in the prior year. The company significantly bolstered its capital, raising $144.6 million through an underwritten registered equity offering and securing an initial $40.0 million from a new $200.0 million Hercules Term Loan Facility. R&D expenses rose to $34.9 million in Q2 2026, and G&A expenses increased to $13.1 million. The company believes its existing cash, cash equivalents, and marketable securities of $494.9 million are sufficient to fund operations for at least one year.